Location History:
- Hong Kong, CN (2014)
- Tai Po, CN (2019)
- New Territories, CN (2023)
Company Filing History:
Years Active: 2014-2025
Title: Innovations of Ka Chun Chong in Nucleic Acid Research
Introduction
Ka Chun Chong is a notable inventor based in Tai Po, China. He has made significant contributions to the field of nucleic acid research, particularly in the context of cancer detection. With a total of 4 patents, his work has advanced the methodologies used in genetic analysis.
Latest Patents
Chong's latest patents focus on determining nucleic acid sequence imbalances associated with cancer using multiple markers. These patents provide methods, systems, and apparatus for identifying whether a nucleic acid sequence imbalance exists within a biological sample. One of the key aspects of his inventions is the selection of cutoff values for determining imbalances in the ratio of two sequences. These cutoff values can be influenced by the percentage of fetal DNA present in a sample, such as maternal plasma, which contains a background of maternal nucleic acid sequences. The percentage of fetal DNA can be calculated using data that also helps determine the cutoff value, particularly at loci where the mother is homozygous and the fetus is heterozygous. Various methods, including sequential probability ratio testing (SPRT), can be employed to establish these cutoff values.
Career Highlights
Chong is affiliated with The Chinese University of Hong Kong, where he continues to engage in innovative research. His work has not only contributed to academic knowledge but also has practical implications in the medical field, particularly in prenatal diagnostics.
Collaborations
Some of his notable coworkers include Yuk-Ming Dennis Lo and Rossa Wai Kwun Chiu. Their collaborative efforts have further enhanced the impact of their research in the scientific community.
Conclusion
Ka Chun Chong's contributions to nucleic acid research exemplify the importance of innovation in medical diagnostics. His patents reflect a commitment to advancing the understanding of genetic imbalances associated with cancer, paving the way for improved detection methods.